HMCC Completes Add-On Investment in CareAbout
Amsterdam, 9th of October 2025 – HMCC, a portfolio company of Holland Capital, proudly announces the successful completion of an add-on investment in CareAbout. This step brings together two strong organizations, joining forces to further support healthcare providers in ensuring continuity of care.
Joining forces
For many years, HMCC has been an innovative medical contact center, supporting general practitioners, pharmacies, and clinics remotely. By adding CareAbout to the group, the two companies can take significant steps together to enhance support for GP practices, pharmacies, and clinics across the Netherlands — both on-site and remotely.
Patrick Eliasar, CEO of HMCC, said: “This partnership enables us to serve our clients even better. By joining forces with CareAbout, we not only broaden our range of services, but also strengthen our team and our shared mission to ensure continuity of care.”
Timothy Hoolhorts, CEO of CareAbout, added: “We are very excited to take this step together with HMCC. This partnership allows us to expand our services and support healthcare organizations more comprehensively — from communication services to staffing solutions.”
Sterre Witteveen, Investment Manager at Holland Capital, commented: “We are impressed by the strong performance of both companies and see great added value in their combination. This partnership aligns perfectly with our broad healthcare portfolio, in which we consistently invest in innovative companies that improve the quality and accessibility of care.”
About HMCC
HMCC specializes in delivering remote healthcare services. The company supports pharmacies, GP practices, and clinics with experienced remote medical assistants, pharmacy assistants, and nurses. HMCC’s services ensure optimal accessibility, efficient workflows, and continuity of care.
About CareAbout
CareAbout recruits and places healthcare professionals with GP practices, pharmacies, and other primary care organizations. It offers both flexible and permanent placements, with personal guidance and professional development opportunities for its healthcare providers.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare and Technology sector. The company has been actively supporting HMCC in its operational and strategic development since joining as a shareholder in 2023.
Magnus Energy en Ciratum bundelen krachten en nemen het voortouw in de energietransitie
Adviesbureaus Magnus Energy en Ciratum bundelen hun krachten om hun dienstverlening te versterken en te verbreden. Om zo innovatieve, hoogwaardige en holistische oplossingen te bieden aan Nederlandse klanten in de energiesector.
Guiding the energy transition: Magnus Energy and Ciratum unite to lead the way
Magnus Energy and Ciratum have joined forces to elevate their service offerings, delivering innovative, high-quality, and holistic solutions to Dutch customers in the energy sector.
Uman raises EUR 1.9m from Holland Capital to disrupt sales enablement market
Uman, the Belgium-based AI-driven software platform for B2B sales teams, raises 1.9 million euros. The funding round is led by Holland Capital, together with existing investors imec and Seeder Fund.
Gentse AI start-up die de perfecte sales pitch genereert, haalt 1,9 miljoen euro op bij Holland Capital
Uman, het Gentse AI-gedreven softwareplatform voor B2B sales teams, haalt 1,9 miljoen euro op. De financieringsronde wordt geleid door Holland Capital, in combinatie met bestaande investeerders imec en Seeder Fund.
Holland Capital kondigt succesvolle exit van Defibrion aan IK Partners aan
Sinds 2019 heeft het management team van Defibrion op succesvolle wijze samengewerkt met Holland Capital. De aandelen van Defibrion worden verkocht aan IK en Defibrion’s management team.
Holland Capital Announces Successful Exit of Defibrion to IK Partners
Since 2019, Defibrion’s management team has successfully collaborated with Holland Capital. The shares of Defibrion are being sold to IK and the company’s management team.
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl



